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Abstract
A goal for developers of immunomodulatory drugs has long been a systemically administered small molecule that can
selectively inhibit inflammation in specific tissues. The chemokine receptor CCR9 is an attractive target for this approach, as
entry of T cells into the small intestine from blood requires interaction between CCR9 and its ligand CCL25. We have tested
the ability of a small molecule CCR9 antagonist, CCX8037, to inhibit antigen-mediated T cell accumulation in the intestine.
This compound prevented accumulation of gut-imprinted antigen-specific CD8 T cells within epithelium of the small
intestine. Interestingly, the antagonist did not affect the robust generation of gut-imprinted CD8 T cells within mesenteric
lymph nodes. To distinguish ‘‘gut-selective’’ from ‘‘general’’ T cell inhibition, we tested the drug’s ability to influence
accumulation of T cells within skin, a tissue in which CCR9 plays no known role, and we found no appreciable effect. This
study demonstrates the feasibility of creating systemically-administered pharmaceuticals capable of tissue-selective
immune modulation. This proof of concept is of utmost importance for designing effective treatments against various
autoimmune disorders localized to a specific tissue.
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Introduction
The circulating T cell pool contains multiple antigen-experi-
enced subsets bearing distinct tissue tropisms. The two best
understood are those associated with skin and intestine. Together,
these two populations comprise at least half of all blood-borne Ag-
experienced T cells [1]. Each subset is responsible for immuno-
logical memory and immunosurveillance of its own target tissue.
In both mice and humans, skin-homing cells express E-selectin
ligand (E-lig) and chemokine receptor 4 (CCR4), while small-
intestine-homing cells express integrin a4b7 and CCR9 [1]. Each
of these molecules is required for normal homing of each cell type
to its respective target organ [2].
Currently available immunosuppressants tend to immunocom-
promise patients overall, leaving them susceptible to opportunistic
infection within any given tissue. In contrast, a tissue-selective
immunomodulatory agent might ameliorate lesions in the affected
site without rendering immunologically healthy tissues vulnerable
to infection. As such, the lymphocyte trafficking field has long held
as its ‘‘holy grail’’ the notion that a systemically administered
pharmaceutical might be designed to selectively attenuate
localized autoimmune symptoms [2]. There is precedent that
blocking the function of homing molecules can affect inflammation
quite dramatically. For example, natalizumab, a humanized
monoclonal antibody against the a4 integrin chain, is FDA
approved as an anti-inflammatory agent (reviewed in [3]).
However, the targeted integrin chain is a component of several
distinct integrin heterodimers, and is not associated with selective
lymphocyte trafficking to any specific tissue [2].
Nonetheless, drugs intended to modulate selective homing of T
cells to particular tissues have not been as uniformly successful as
previously hoped [4]. The disappointing outcome of this approach
to date may be partially explained by the discovery that many
tissue-selective homing mechanisms rely on competition among
lymphocyte subsets for entry into tissue from the circulation. For
example, normal T cells are 20-fold more likely to accumulate
within inflamed skin than otherwise identical cells that lack CCR4
[5,6,7]. However, CCR4
2/2 T cells do gain access to skin when
such competition is removed; CCR4
2/2 mice have relatively
normal densities of T cells in both inflamed and resting skin [8].
Thus, CCR4 is required for skin homing only in a physiologically
PLOS ONE | www.plosone.org 1 November 2012 | Volume 7 | Issue 11 | e50498competitive environment. Ablation of the CCR4 function alters
the environment such that CCR4 is no longer needed for skin
homing. Less efficient (perhaps even non-physiological) mecha-
nisms may then take over in guiding lymphocytes into tissues.
Homing of T cells to the intestine appears to provide a more
promising target for tissue-selective pharmaceutical manipulation.
Humanized antibodies to the integrin heterodimer a4b7 (vedoli-
zumab) or its ligand MAdCAM-1 (PF-00547,659) have provided
clinical improvements in ulcerative colitis and Crohn’s disease in
Phase I and II trials (reviewed in [3]).
A small molecule antagonist of CCR9 recently demonstrated
efficacy in the PROTECT-1 clinical trial for Crohn’s disease
(reviewed in [9,10,11]). The ability of an antagonist of this nature
to modulate a local immune response within a tissue, after systemic
dosing, while allowing normal immune function in other tissues
has not been described previously. We therefore tested a murine-
optimized version of this drug in mouse models of skin and gut
inflammation to assess its relative efficacy in cutaneous versus
intestinal inflammation.
We found that the inhibition of CCR9 function with a specific
antagonist is extremely effective at excluding Ag-specific inflam-
matory CD8 T cells from intestinal epithelium, without impacting
the recruitment of antigen-specific cells to the inflamed skin. To
our knowledge this is the first direct evidence that a systemically
administered small molecule can effectively treat inflammation in
a tissue-selective manner.
Results and Discussion
CCX8037 is a Potent and Selective CCR9 Antagonist
CCR9 dependent chemotaxis can be readily assessed in vitro
using the Molt-4 T cell line, which endogenously expresses CCR9
and responds to CCL25 with a stereotypical bell-shaped chemo-
taxis curve in standard in vitro chemotaxis assays [11]. CCX8037 is
a potent inhibitor of CCL25-mediated Molt-4 chemotaxis in
buffer (0.1% BSA in HBSS) with an IC50 of 12 nM (Fig. 1A). In
order to assess the potency of this molecule under physiologically
relevant conditions, chemotaxis assays were performed in the
presence of 100% human AB serum: CCX8037 inhibited CCL25-
induced Molt-4 chemotaxis with an IC50 of 32 nM under these
conditions (Fig. 1B). In addition to inhibiting CCL25-induced
chemotaxis, CCX8037 also inhibits CCL25-induced Ca
2+ mobi-
lization in Molt-4 cells with an IC50 of 19 nM (Fig. 1C) To
determine its potency against mouse CCR9, a murine thymocyte
chemotaxis assay was performed. CCX8037 inhibited CCL25-
induced chemotaxis of murine thymocytes with an IC50 of 2.5 nM
(Fig. 1E).
The selectivity of CCX8037 for CCR9 was assessed in real time
using IL-2 cultured lymphocytes that were stimulated sequentially
with the indicated chemokines (Fig. 1D) in the presence of either
0.1% DMSO or 10 mM of compound. Cells stimulated in the
presence of CCX8037 did not exhibit any appreciable reduction
in chemokine induced Ca
2+ mobilization relative to the DMSO
control for any of the non-CCL25 chemokines tested.
CCR9 Antagonist Inhibits Homing of OT-I CD8 T Cells to
the Intestinal Epithelium after Oral Immunization
To evaluate the effectiveness of CCX8037 at inhibiting
CCR9-mediated chemotaxis and trafficking in vivo, we modified
a model system that we employed previously to study the role of
CCL25 in homing of CD8 T cells to the small intestinal
epithelium (IE) [12]. Congenically marked CD45.1
+ CD8 T
cells from TCR-transgenic OT-I mice (specific for ovalbumin
peptide OVA257-264 in the context of H-2K
b) [13] were
adoptively transferred into WT CD45.2
+ mice. One day
following adoptive transfer, mice were administered adjuvant
(cholera toxin (CT)) by oral gavage, with or without antigen
(OVA). Those mice that received both adjuvant and antigen
were split into two treatment groups. Each group received
subcutaneous injections of either saline alone (control group) or
30 mg/kg CCX8037 in saline (experimental group) every 12
hours. The dose of CCX8037 administered to the experimental
group was designed to sustain plasma concentrations at or
above the serum adjusted IC90 of 320 nM during the 12 hours
between injections (The IC90 represents the concentration of
CCX8037 that is required to block 90% of the CCL25-induced
chemotaxis response). This regimen was maintained for 5 days
post immunization, after which the mice were sacrificed and
lymphocyte cell suspensions were prepared from MLN and
intestinal epithelium (IE). Blood samples were taken at the time
of sacrifice to confirm that drug levels were at the IC90 of
320 nM (data not shown). [Note: oral gavage is often used as a
technique for generating immune tolerance. This is not relevant
in this case, as the CT adjuvant effectively breaks induction of
tolerance [12]].
We found the proportion of donor-derived OT-I cells within the
total CD8 T cell population of IE to be reduced by ,6-fold in
mice treated with CCX8037 (Fig. 2A and 2B). Interestingly, this
reduction was similar in magnitude to that seen for OT-I cells
transferred to mice congenitally lacking CCL25 [12]. The number
of OT-I CD8 T cells found in the IE was negligible in mice that
received only adjuvant (Fig. 2B).
The reduction of OT-I cells within the total CD8 T cell
intestinal epithelium population after treatment does not by itself
imply the mechanism of action. The CCR9 antagonist may indeed
interfere directly with CCR9-mediated homing to intestinal
epithelium. However, the reduction could be explained equally
well by effects of CCX8037 within the GALT, acting to reduce
Ag-induced OT-I proliferation, or to reduce differentiation of
naı ¨ve precursors into gut-selective memory or effector populations
that express intestinal homing markers.
To distinguish among these possibilities, we analyzed OT-I cells
from a representative GALT tissue, the mesenteric lymph node
(MLN), to assess their proliferation and gut-selective differentiation
status. We used CD44 as a marker to distinguish naı ¨ve cells
(CD44
lo) from those that had previously responded to cognate Ag
(CD44
hi). In the absence of Ag, OT-I cells comprised only ,2% of
the total CD44
hi CD8 T cell population in MLN (Fig. 2C). After
immunization, OT-I cells increased to ,30% of the total CD44
hi
CD8 T cell population. Importantly, the presence of CCX8037
did not appreciably influence Ag-specific proliferation in this assay
(Fig. 2C).
We next examined the Ag-induced expression of gut-tropic
homing molecules (i.e. tissue-specific imprinting) [14] on OT-I
cells within the MLN. We assessed expression of b7-integrin
and CCR9 by flow cytometry. Oral immunization with OVA
caused dramatic increases in b7 and CCR9 expression, but
CCX8037 did not appreciably affect expression of either
molecule alone or in combination (Fig. 2D). These homing
molecules were rarely present on OT-I cells in the mice
immunized orally with adjuvant only. Thus, a reduction in gut-
specific Ag-induced imprinting within GALT does not explain
the CCX8037-induced reduction of OT-I cells within the
intraepithelial CD8 T cell pool.
Taken together, these data strongly suggest that the effects
mediated by CCX8037 in intestinal epithelium are due to direct
interference with the trafficking of Ag-specific T cells into the
tissue.
CCR9 Antagonist Selectively Blocks Homing to Gut
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Unaffected by CCR9 Antagonist
The prior experiments did not rule out the possibility that
CCX8037 caused a general defect in trafficking of CD8 T cells to
all peripheral tissues. To see if this was the case, we tested the
ability of CCX8037 to inhibit Ag-specific accumulation of OT-I
cells within the skin [1]. OT-I CD8 T cells were adoptively
transferred into WT CD45-congenic recipients exactly as
performed in the gut-homing studies above. Animals were
immunized topically on the ear skin with either CT only or with
CT + OVA. As above, animals that received both antigen and
adjuvant were split into two groups for injection of CCX8037 or
vehicle every 12 hours. Mice were sacrificed 5 days post
immunization and cell suspensions were prepared directly from
the inflamed ear skin and from the cervical lymph nodes (cLN),
which are the lymphoid organs that directly drain the site of
inflammation.
In striking contrast to the findings in gut, CCX8037 did not lead
to any appreciable reduction in the proportion of CD8 T cells
within skin that were derived from the OT-I donor (Figs. 3A and
B). Ag-induced proliferation of OT-I cells within the cLN was not
affected by CCX8037, nor was their imprinting with the skin-
homing molecule E-lig (Fig. 3C and 3D).
Unlike gut-selective homing of CD8 T cells, skin specific
homing does not depend upon CCR9 function. Having shown
that CCX8037 compromises CD8 T cell homing to the gut, but
not to the skin in vivo, we find that a small molecule drug can be
administered systemically to selectively inhibit CCR9-mediated
trafficking of CD8 T cells to the small intestine.
Concluding Remarks
In this study, we have demonstrated in vivo that a small molecule
inhibitor of CCR9 can prevent T cell accumulation within
inflamed intestine without affecting inflamed skin. We believe this
to be the first clear-cut in vivo example of a small molecule able to
modulate tissue-selective T cell mediated immunity, a strategy that
may well be used to modulate autoimmune syndromes in the
intestine, as well as autoimmune syndromes in other tissues.
Materials and Methods
Ethics Statement
All experimental procedures involving animals were approved
by the Children’s Hospital Boston (CHB) IACUC (protocol number
10-04-1645R), which oversees the facility in which these proce-
dures were performed.
Mice
C57BL/6 n mice (CD45.2
+) were purchased from Charles
River Labs (Wilmington, MA). OT-I Tg mice were bred onto the
CD45.1 C57BL/6 n background ((B6.SJL-Ptprca Pep3b/BoyJ; The
Jackson Laboratory). Animals were housed under SPF conditions.
Cell Culture, Chemotaxis and Mountain Peak Assays
Molt-4 cells were obtained from the ATCC (Manassas, VA) and
cultured in RPMI-1640 (Invitrogen, Carlsbad, CA) supplemented
with 10% FCS (Invitrogen, Carlsbad, CA) in a humidified 5%
CO2 incubator at 37uC. Chemotaxis assays were conducted as
previously described [11], responding cells were quantified by the
Figure 1. CCX8037 is a potent and selective antagonist of CCR9. CCL25-induced chemotaxis was measured on Molt-4 cells and murine
thymocytes by using a DNA intercalating fluorescent dye (CyQUANT) to quantify responding cells and is labeled as the ‘‘migration signal’’, as the
relative fluorescence of the migrated population is proportional to the number of cells that migrated. Six to eight replicates were performed per data
point. Calcium flux was measured on Molt-4 cells or IL-2-cultured lymphocytes loaded with Indo-1AM dye and exposed to IC50 concentrations of the
chemokines indicated. A) CCX8037 inhibits CCL25-induced Molt-4 chemotaxis in buffer (0.1% BSA in HBSS) with an IC50 of 12 nM (n=31). B) CCX8037
inhibits CCL25-induced Molt-4 chemotaxis in the presence of 100% human AB serum with an IC50 of 32 nM (n=9). C) CCX8037 inhibits CCL25-
mediated mobilization of intracellular Ca2+ in Molt-4 cells with an IC50 of 19 nM (n=3). D) CCX8037 (blue trace; 10 uM) does not inhibit chemokine
induced mobilization of intracellular Ca2+ to EC50 concentrations of CCL4(CCR5), CCL15 (CCR1) on IL-2 activated lymphocytes. E) CCX8037 inhibits
CCL25-induced murine thymocyte chemotaxis in buffer with an IC50 of 2.5 nM (n=2).
doi:10.1371/journal.pone.0050498.g001
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resulting fluorescence using a Spectraflour Plus plate reader
(Tecan, Grodig, Austria). Mouse thymocytes for determining the
murine potency of CCX8037 were isolated from 3–6 week old
C57BL/6 mice (The Jackson Laboratory, Sacramento CA).
Mountain peak assays were performed using IL-2 cultured
lymphocytes as previously described [11].
Compound
CCX8037 was provided by Dr. J. Powers, Medicinal Chemistry
Department , ChemoCentryx (Mountain View, CA).
Adoptive Transfers and Immunizations
Adoptive transfers were performed as described previously[12].
Briefly, single cell suspensions were prepared from spleens and
lymph nodes of OT-I Tg CD45.1 mice. 3610
6 CD45.1 CD8 T
cells were injected retro-orbitally into sex-matched congenic
CD45.2 C57BL/6 n mice (8–10 weeks old). 24 hours later,
animals were either immunized via oral gavage with 5 mg
Ovalbumin protein (Sigma-Aldrich, St. Louis, MO) + 10 mg
Cholera Toxin (Calbiochem, San Diego, CA), or epicutaneously
on the ear skin with 300 mg OVA257–264 peptide (Biomatik,
Ontario, Canada) and 100 mg Cholera toxin by ear painting after
tape stripping and acetone treatment as described previously[6].
Isolation of Lymphocytes from Intestinal Epithelium
IEL from the small intestine were isolated as described: Peyer’s
Patches were removed and, after flushing with PBS, the gut was
opened longitudinally and laterally into 0.5-cm pieces. The small
intestinal mucosa was then dissociated by stirring in 25 ml of
Figure 2. CCX8037 reduces accumulation of OT-I CD8 T cells in the intestinal epithelium without affecting gut homing tropism,
imprinting and proliferation. Animals were injected with 3e6 OT-I CD8 T cells, and immunized 24 hours via oral gavage with either 10 mg Cholera
Toxin (CT) only, or CT + 25 mg Ovalbumin (OVA). Animals given OVA were also injected subcut. every 12 hours for the course of the study with
CCX8037 (30 mg/kg) or vehicle. Mice were sacrificed for analysis 5 days post immunization. Mean and SEM shown for each data point, p values
indicate Bonferroni multiple comparison post test. (A) Representative flow cytometry plot showing the accumulation of CD44
hi CD8 T cells, and
gating of OT-I (CD45.1) cells in the intestinal epithelium. Plots are pre-gated on CD3e
+/CD8a
+ cells. (B) Quantification of OT-I CD8 T cell accumulation
in intestinal epithelium. Mice fed CT only did not exhibit substantial OT-I CD8 T cell homing into the intestinal epithelium. Animals fed CT + OVA and
treated with vehicle had significant OT-I CD8 T cell homing, with 27.9% of all resident CD8 T cells being OT-I derived. Animals fed CT + OVA and
injected with CCX8037 exhibited significantly reduced intestinal epithelium accumulation of OT-I CD8 T cells, to 4.7%. N=13 mice for CCX8037 and
vehicle groups, and 6 for CT only. (C) CCX8037 did not affect the proliferation of OT-I CD8 T cells in MLN after Ag exposure. In animals exposed to CT
only, OT-I CD8 T cells composed 1.8% of all CD44
hi CD8 T cells. In animals exposed to CT + OVA, there was no significant difference in the percentage
of CD44
hi CD8 T cells that are OT-I between those treated with vehicle (29.7%) and CCX8037 (27.6%). N=6 for CT only treated mice, N=13 for Vehicle
and CCX8037 treated mice. (D) Generation of gut homing molecules on OT-I CD8 T cells in MLN was not affected by CCX8037. Animals not fed OVA
antigen had significantly lower b7
+, CCR9
+,o rb7
+CCR9
+ expression. However, the expression of gut homing molecules was not significantly affected
by CCX8037 treatment, compared to vehicle. OT-I CD8 T cells of vehicle and CCX8037 treated mice were 45.6% and 49.1% b7
+ respectively, 44.7% and
44.1% CCR9
+ respectively, and 36.3% and 36.1% b7
+CCR9
+ respectively. N=13 mice for CCX8037 and vehicle groups, and 6 for CT only.
doi:10.1371/journal.pone.0050498.g002
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for 2 times 20 min at 37uC. IEL were further purified on a 40%–
80% Percoll gradient.
Isolation of CD8 T Cells from Skin
Lymphocytes were isolated from skin as follows: ears were
harvested from mice, and dorsal and ventral surfaces were split
apart with forceps. Ear halves were diced into ,0.5 mm pieces.
Ear pieces were incubated in HBSS + 2 mM EDTA + 10 mM
HEPES for 4 hours at 4uC with constant brisk stirring. Ear
solution was passed through a 40 mM filter, and cells were
centrifuged from the suspension, and washed 2X with PBS + 10%
bovine Serum.
Flow Cytometry
All flow cytometry was performed on a BD FACS Canto flow
cytometer. Antibodies and staining reagents were obtained from
eBioscience (San Diego, CA), BD Pharmingen (San Diego, CA),
R&D systems (Minneapolis, MN), and Jackson Immunoresearch
(West Grove, PA). Analysis of flow cytometry data was performed
using Treestar FlowJo v.8.8.2 (Ashland, OR), and Graphpad
Prism v.5.0a (La Jolla, CA).
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Figure 3. CCX8037 does NOT reduce accumulation of OT-I CD8 T cells in the skin. Animals were injected with 3e6 OT-I CD8 T cells, and
epicutaneously immunized 24 hours later on the ear skin. Ear skin was painted with either 100 mg Cholera Toxin (CT) only, or 100 mgC T+ 100 mg
OVA257–264. Animals treated with OVA257–264 were split into two groups and received subcut. injections of CCX8037 or vehicle every 12 hours for the
course of the study. Mice were sacrificed for analysis 5 days post immunization. Mean and SEM shown for each data point, p values indicate
Bonferroni multiple comparison post test. (A) Representative flow cytometry plot showing the accumulation of CD44
hi CD8 T cells, and gating of OT-I
(CD45.1) cells in the ear skin. Plots are pre-gated on CD3e
+ CD8a
+ cells. (B) Quantification of OT-I CD8 T cell accumulation in ear skin. Mice treated
with CT only did not exhibit substantial OT-I CD8 T cell homing into the ear skin. Mice treated CT + OVA257-264 and treated with vehicle had significant
OT-I CD8 T cell homing, with 79.6% of all resident CD8 T cells being OT-I derived, while those treated with CCX8037 had 80.2% of all CD8 T cells being
OT-I derived. N=5 groups for vehicle, 6 for CCX8037 and 3 for CT only. Each group was comprised of 3–5 pooled mice. (C) CCX8037 did not affect the
proliferation of OT-I CD8 T cells in CLN after Ag exposure. In animals exposed to CT only, OT-I CD8 T cells composed 1.4% of all CD44
hi CD8 T cells. In
animals exposed to CT + OVA, there was no significant difference in the percentage of CD44
hi CD8 T cells that are OT-I between those treated with
vehicle (26.0%) and CCX8037 (30.1%). N=3 groups for CT only treated mice, N=6 groups for Vehicle and CCX8037 treated mice, where each group is
3–5 pooled mice. (D) Generation of skin homing associated molecule E-selectin ligand by OT-I CD8 T cells in CLN was not affected by CCX8037. When
mice were immunized with OVA antigen, the E-lig was not significantly affected by the presence of the CCX8037 (38.4% vehicle, 43.3% CCX8037). In
the absence of OVA antigen, E-lig production by OT-I CD8 T cells was negligible (,1% E-lig
+). N=4 for CT only, 16 for Vehicle and CCX8037.
doi:10.1371/journal.pone.0050498.g003
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